ANALYSIS OF SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS IN THE TREATMENT OF PATIENTS WITH FIBROMYALGIA AT AN INSTITUTION IN WESTERN PARANÁ

Abstract

Fibromyalgia is a syndrome characterized by symptoms and signs that relate to multiple areas of medicine, commonly defined as widespread pain and tenderness upon palpation, associated with joint stiffness, fatigue, and sleep disturbance. It is one of the most prevalent musculoskeletal disorders and constitutes a primary diagnosis in rheumatology practices, with a general population prevalence of 2% according to the European Alliance Of Associations For Rheumatology (EULAR). There are multiple therapies for fibromyalgia, both non-pharmacological and pharmacological, but there is no consensus regarding their efficacy. Currently, the most widely used and studied medications for this syndrome are antidepressants, including tricyclics and dual-action agents (selective serotonin and norepinephrine reuptake inhibitors). Dual-action antidepressants are better tolerated by patients due to their lower side effects and analgesic effects.